THSNA 2024 - Chicago, IL

PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

Workshop Schedule

SATELLITE SYMPOSIA

Host a Satellite Symposium

Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2024 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.

Wed - Apr 03

Thu - Apr 04

Fri - Apr 05

Sat - Apr 06

View Program Details

THURSDAY, APRIL 4

6:45 - 6:30 PM

EVENT/OTHER

REGISTRATION
Chicago Promenade

7:15 - 8:15 AM

SATELLITE SYMPOSIUM

READY, SET, GO! SHAPE THE FUTURE OF CARE IN VON WILLEBRAND DISEASE (SPONSORED BY OCTAPHARMA)
Chair/Organizer: Veronica Flood
Chicago Ballroom VI

Join our distinguished faculty; Dr Veronica Flood, Dr Jill Johnsen, and Dr Shveta Gupta to explore the future of care in von Willebrand disease. The panel will discuss the diagnosis of von Willebrand disease, including identification of iron deficiency and genotyping, and the importance of prophylaxis in VWD patients. The results of the WIL-31 study will be presented, the largest prospective prophylaxis study in von Willebrand disease with an on-demand run-in study as an intra-individual patient comparator. We look forward to seeing you in Chicago!

7:15

WELCOME AND INTRODUCTION
Veronica Flood.

7:20

IDENTIFYING AND ADDRESSING UNMET PATIENT NEEDS IN VWD
Veronica Flood.

7:35

INSIGHTS FROM THE LARGEST PROSPECTIVE PROPHYLAXIS STUDY IN VWD: WIL-31
Shveta Gupta.

7:50

VWD GENOTYPING: EMPOWERING PRECISE DIAGNOSIS AND PERSONALIZED CARE
Jill Johnsen.

8:05

Q&A AND CONCLUDING REMARKS.

REINFORCING 10+ YEARS OF CLINICAL TRIAL EXPERIENCE WITH A SUBCUTANEOUS PROPHYLAXIS TREATMENT, INCLUDING THE LATEST DATA IN INFANTS: JOIN THE CONVERSATION WITH DR. MIKE SILVEY (SPONSORED BY GENENTECH)
Chicago Ballroom IX-X

Please join us for an engaging program led by Dr. Mike Silvey as he shares his perspectives on managing patients with hemophilia A using a subcutaneous prophylactic treatment. The presentation will include the pivotal efficacy and safety data that is the foundation of the ongoing clinical trial program in patients with and without FVIII inhibitors, including an overview of real-world experience. Hell also share updates from the latest trial in infants and previously untreated patients. The presentation will feature brain teasers, showcase social media thats engaging the hemophilia community, and Mythbuster polls. Be sure to bring your questions to the Q&A following the program.

8:30 - 9:45 AM

PLENARY SESSION

THE RISE OF THE PATIENT ADVOCATE - IMPACTING RESEARCH, TREATMENT, AND OUTCOMES
Chair/Organizer: Lena Volland, Kristi Smock
Sheraton Ballroom IV-V

8:30

HOW THE CLUES AND PEP SURVEYS CHANGED THE MENTAL HEALTH LANDSCAPE FOR PATIENTS AND HCP'S
Rushad Patell.

8:55

THE ROLE OF SOCIAL MEDIA IN EDUCATING THE PATIENTS AND CLINICIANS
Lelise Lake.

9:20

THE ROLE OF PATIENT ADVOCACY GROUPS IN DRIVING INNOVATION
Maria Santaella.

9:45 - 10:30 AM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Riverwalk AB

Coffee break sponsored by Spark Therapeutics, Inc.

A1. ANTICOAGULATION CLINICS

101

UNFRACTIONATED HEPARIN USE IN THE SETTING OF ACUTE PULMONARY EMBOLISM
David Scott¹, Zhongyuan Chen¹, Aniko Szabo¹, Lindsay Hammons¹, Lisa Baumann Kreuziger^{1, 2}. ¹Medical College of Wisconsin, Milwaukee, WI, USA. ²Versiti Blood Center, Milwaukee, WI

A2. PLATELET ACTIVATION AND BIOCHEMISTRY

102

IN VIVO VOLUME ELECTRON MICROSCOPY ANALYSIS AT THE SINGLE CELL LEVEL REVEALS REGIONAL INCREASES IN PLATELET SHAPE DISPERSITY ACROSS A MOUSE, JUGULAR VEIN PUNCTURE WOUND THROMBUS
Madhavi A. Ariyarathne¹, Irina D. Pokrovskaya¹, Oliver S. Zhao², Richard D. Leapman², Maria A. Aronova², Brian Storrie¹. ¹University of Arkansas for Medical Sciences, Little Rock, AR, USA. ²National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA

A4. DISORDERS OF PLATELET NUMBER OR FUNCTION

103

LONG-TERM EFFICACY AND SAFETY WITH ORAL BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
David J Kuter¹, Terry Gernsheimer², Waleed Ghanima³, Umer Khan⁴, Brad Ward⁵, Ahmed Daak⁵, Nichola Cooper⁶. ¹Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ²University of Washington Medical Center, Seattle, WA, USA. ³A, Gralum, Norway. ⁴Biostatistics, Sanofi, Bridgewater, NJ, USA. ⁵Sanofi, Cambridge, MA, USA. ⁶Department of Medicine, Hammersmith Hospital, London, United Kingdom

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

104

RISK FACTORS ASSOCIATED WITH VENOUS THROMBOEMBOLISM IN CHRONIC LYMPHOCYTIC LEUKEMIA
Ambarina Faiz¹, Shuang Guo¹, Ashwin Sridharan¹, Yong Lin^{2, 3}, Claire Philipp¹. ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. ²Rutgers School of Public Health, Piscataway, NJ, USA. ³Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

105

OUTCOMES AND PREDICTORS OF IMMUNE THROMBOCYTOPENIA IN HOSPITALIZATIONS FOR ANTIPHOSPHOLIPID SYNDROME: A NATIONWIDE INPATIENT SAMPLE ANALYSIS
Michael Imeh¹, Ani Gvajaia¹, Chukwunonye Amaeshi², Fidelis Uwumiro³. ¹Lincoln Medical and Mental Health Centre, Bronx, NY, USA. ²Montefiore Medical Centre, Bronx, NY, USA. ³University of Benin Teaching Hospital, Benin, Nigeria

106

THE P. D1472H POLYMORPHISM IN THE VWF GENE IS COMMON IN INDIAN PATIENTS
Ritika Sharma, Manu Jamwal, Harikishen Senee, Narender Kumar, Arihant Jain, Pankaj Malhotra, Deepak Bansal, Reena Das, Jasmina Ahluwalia. Postgraduate Institute of Medical Education and Research, Chandigarh, India

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

107

IRON DEFICIENCY HAS GENERALLY NOT BEEN CONSIDERED WHEN DEFINING SEX-BASED HEMOGLOBIN REFERENCE INTERVALS: A SYSTEMATIC REVIEW
Ingrid Blydt-Hansen¹, Vidushi Swarup², Teruko Kishibe³, Carine Bekdache², Vanessa Giuliano⁴, Rebecca Sampat², Rowan Thillaye-Kerr², Angela Weyand⁵, Mark Crowther⁶, Miranda Wozniak⁷, Grace H Tang⁸, Michelle Sholzberg⁸. ¹Department of Internal Medicine, University of British Columbia, Vancouver, BC, Canada. ²Hematology-Oncology Clinical Research Group, Division of Hematology-Oncology, St. Michael's Hospital, Toronto, Canada, Toronto, ON, Canada. ³Health Sciences Library, St. Michaela, Toronto, ON, Canada. ⁴Department of Medicine, University of Toronto, Toronto, ON, Canada. ⁵Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA. ⁶Department of Medicine, McMaster University, Hamilton, ON, Canada. ⁷Department of Laboratory Medicine a Pathobiology, Hematological Pathology, University of Toronto, Toronto, ON, Canada. ⁸Departments of Medicine, and Laboratory Medicine and Pathobiology, St Michaela, Toronto, ON, Canada

108

COAGULATION PROFILE AND CLOT STIFFNESS ANALYSIS FROM COVID-19-POSITIVE PATIENTS USING A NOVEL VISCOELASTICITY TESTING TECHNOLOGY
Dimitria Bonizol Camasao^{1, 2+}, Jose G. Munguia-Lopez¹⁺, Anna Perez⁵, JosAc A. Correa³, Cedric Schmitt², Anis Hadj Henni², Chantal SAcguin⁴, Donald C. Vinh⁵, Showan N. Nazhat^1*. ¹Department of Mining and Materials Engineering, McGill University, Montreal, QC, Canada. ²Rheolution Inc, Montreal, QC, Canada. ³Department of Mathematics and Statistics, McGill University, Montreal, QC, Canada. ⁴Department of Medicine, Division of Hematology, McGill University Health Centre, McGill University, Montreal, QC, Canada. ⁵Department of Experimental Medicine, Division of Infectious Diseases, McGill University Health Centre, McGill University, Montreal, QC, Canada

109

IMPACT OF ANTICOAGULATION IN ACQUIRED HEMOPHILIA A
Heather Frazier, Sean Dougherty, Kia Salafian, Hillary Maitland. University of Virginia, Charlottesville, VA, USA

110

PRELIMINARY FINDINGS OF UTILIZING APTT ASSAY AS A SCREENING TOOL FOR LUPUS ANTICOAGULANT
Suhhyun Kim, Daniel Sabath. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA

111

TIMELINESS OF HEMOSTATIC THERAPY ADMINISTRATION FOR PATIENTS WITH BLEEDING DISORDERS IN THE EMERGENCY DEPARTMENT
Emily Kraft, Vanessa Bourck, Yuxin Zhang, Lisa Duffett, Alan Tinmouth, Tzu-Fei Wang, Roy Khalife. Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada

112

EVALUATION OF REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH VON WILLEBRAND DISEASE TREATED PROPHYLACTICALLY WITH RECOMBINANT VON WILLEBRAND FACTOR ACROSS TREATMENT CENTERS IN THE UNITED STATES
Jonathan C Roberts¹, Maissaa Janbain², Jessica R Marden³, Sanjana Sundaresan³, Natalia Nieto⁴, Bethany Jones⁴, Jorge Caicedo⁴. ¹Bleeding a Clotting Disorders Institute, Peoria, IL, USA. ²Tulane University School of Medicine, New Orleans, LA, USA. ³Analysis Group, Inc, Boston, MA, USA. ⁴Takeda Pharmaceuticals U. S. A, Inc, Lexington, MA, USA

113

THE RELATIONSHIP BETWEEN DIFFERENT PAIN MEASURES, DEPRESSION, AND SOCIAL SUPPORT AND RACE AND ETHNICITY IN PERSONS WITH HEMOPHILIA.
Maria E Santaella, Matthew Hartnett, Luke Luckey, Cynthia D Nichols. National Bleeding Disorders Foundation, New York, NY, USA

114

BLEEDING DUET: A CASE OF SIMULTANEOUS ACQUIRED FACTOR VIII DEFICIENCY AND ACQUIRED VON WILLEBRAND SYNDROME
Richard Yu¹, Mathew Strelau¹, Thunisa Shanmugalingham¹, Mackenzie Bowman², Arnaud Bonnefoy³, Paula James², Chai Phua¹. ¹University of Western Ontario, Department of Hematology, London, ON, Canada. ²Queens University, Department of Hematology, Kingston, ON, Canada. ³University of Montreal, Department of Hematology, Montreal, QC, Canada

A8. ANTITHROMBOTIC THERAPY

115

THE IMPACT OF A HIGH-RISK ANTICOAGULATION PRESCRIBING STEWARDSHIP SCORING TOOL IMPLEMENTATION IN AN INPATIENT SETTING
Emma Baker¹, John Lindsley¹, Ian Watt¹, Rakhi Naik², Michael Streiff², Jennifer Yui², Kathryn Dane¹. ¹The Johns Hopkins Hospital Department of Pharmacy, Baltimore, MD, USA. ²Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA

116

DOES UNFRACTIONATED HEPARIN VERSUS LOW MOLECULAR WEIGHT HEPARIN FOR THROMBOPROPHYLAXIS REDUCE COMPLICATIONS NEAR DELIVERY?
Sophia A. Cordes, Hani Faysal, Joaquin A. Calderon, Renxi Li, Sonya T. Gelfand, Mina Felfeli, Haeun Kim, Homa K. Ahmadzia. Department of Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA

117

RIVAROXABAN IN OLDER ADULTS WITH NONVALVULAR ATRIAL FIBRILLATION: POPULATION-BASED ANALYSIS IN RESPONSE TO UPDATED BEERS CRITERIA
Ghadeer Dawwas¹, Adam Cuker². ¹Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA. ²Department of Medicine, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

118

MONITORING BIVALIRUDIN THERAPY USING A BIVALIRUDIN-SPECIFIC CHROMOGENIC ANTI-IIA ASSAY
Sean G Yates¹, Ravi Sarode¹, Sarita Paulino¹, Ibrahim F Ibrahim², Lisa K Skariah³. ¹Department of Pathology, Division of Transfusion Medicine and Hemostasis, University of Texas Southwestern Medical Center, Dallas, TX, USA. ²Department of Internal Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. ³UT Southwestern Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas, TX, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

119

INFLUENCE OF PHARMACEUTICAL INDUSTRY ON PUBLISHED CLINICAL TRIAL RESULTS
Divyanka Kavdikar¹, Siddharth Suresh¹, Fakiha Siddiqui², Atul Laddu¹, Jawed Fareed², Arav Raghunathan¹, Ishvari Mokadam¹. ¹Global Thrombosis Forum, Suwanee, GA, USA. ²Loyola University, Chicago, IL, USA

120

CLINICAL EXPERIENCE USING REGIONAL CITRATE ANTICOAGULATION IN CONTINUOUS RENAL REPLACEMENT THERAPY IN A NEONATE WITH ACUTE KIDNEY FAILURE: CASE REPORT
Jessica Santoyo Cueva¹, Luis Ruben Miranda Ramirez¹, Michelle Cecilia Arechiga Andrade¹, Erendira Reyes Ramirez¹. ¹Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico. ²Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico. ³Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico. ⁴Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico

10:30 - 11:30 AM

SHORT TALKS

SHORT TALKS - COMPLICATIONS OF DISEASE AND THERAPY IN H&T
Chair/Organizer: Bethany Samuelson Bannow, Emma DeLoughery
Sheraton Ballroom I-II

10:30

EFFICACY OF RADIOTHERAPY FOR HEMOSTASIS IN TUMOR-RELATED BLEEDING
Emma P. DeLoughery, Byron Wilson, Aaron Grossberg. Oregon Health a Science University, Portland, OR, USA

10:45

OSTEOPOROSIS AND FRAGILITY FRACTURES IN HEMOPHILIA AND VON WILLEBRAND DISEASE - A LARGE NATIONAL CLAIMS DATABASE STUDY
Divyaswathi Citla Sridhar¹, Brandi Dupervil², Laura Schieve², Sanjay Ahuja³, Marilyn Manco-Johnson⁴, Roshni Kulkarni⁵, Suchitra Acharya⁶, Meera Chitlur⁷, Patricia Tobase⁸, Anjali Sharathkumar⁹, Binh Le², Mike Soucie². ¹University of Arkansas for Medical Sciences/ Arkansas Children's hospital, Little Rock, AR, USA. ²Centers for Disease Control and Prevention, Atlanta, GA, USA. ³Case Western Reserve University, Cleveland, OH, USA. ⁴Hemophilia a Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ⁵Centers for Bleeding and Clotting Disorders, Department of Pediatrics, Michigan State University, Lansing, MI, USA. ⁶Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, New Hyde Park, NY, USA. ⁷Division of Hematology/Oncology, Childrena, Detroit, MI, USA. ⁸University of California San Francisco, San Francisco, CA, USA. ⁹Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa Health Care, Iowa City, IA, USA

11:00

HEALTHCARE BURDEN OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED CANCER PATIENTS: NATIONALLY REPRESENTATIVE ESTIMATES USING THE LARGEST ALL-PAYER INPATIENT DATABASE IN THE UNITED STATES
Krish Khurana¹, Giuseppe Maiocco², Nareg H. Roubinian³, Mohammad Hussain², Waqas Azhar², Sujitha Ketineni², Hareena Sangha⁴, Michael B. Streiff⁵, Aaron A. R. Tobian⁵, Ruchika Goel^{2, 5, 6}. ¹Southern Illinois School of Medicine P4P program, Springfield, IL, USA. ²Southern Illinois School of Medicine, Springfield, IL, USA. ³Vitalant Research Institute, San Francisco, CA, USA. ⁴University of Texas Southwestern School of Medicine, Dallas, TX, USA. ⁵Johns Hopkins University School of Medicine, Baltimore, MD, USA. ⁶Vitalant Corporate Medical Affairs, Scottsdale, AZ, USA

11:15

HEPARIN-INDUCED THROMBOCYTOPENIA AMONG CANCER HOSPITALIZATIONS: A TEN YEAR RETROSPECTIVE STUDY
Ayobami Olafimihan¹, Praise Fawehinmi², Ekrem Turk¹, Gbolahan Olatunji³, Emmanuel Kokori³, Aderinto Nicholas ⁴, oh youjin¹, Chiamaka Nwachukwu⁵, Shaka Hafeez¹. ¹John H. Stroger Jr Hospital, Chicago, IL, USA. ²Southern Illinois University Edwardsville, Edwardsville, IL, USA. ³University of Ilorin, Ilorin, Nigeria. ⁴Ladoke Akintola University of Technology, Ogbomosho, Nigeria. ⁵Tulane University School of Medicine, new orleans, LA, USA

SHORT TALKS - INDUSTRY BLEEDING - NO CME
Chair/Organizer: Julie Jaffray, Johnathan Morris
Chicago Ballroom VII

10:30

IMPROVED JOINT HEALTH AFTER GENE THERAPY WITH DIRLOCTOCOGENE SAMOPARVOVEC (SPK-8011) IN PEOPLE WITH HEMOPHILIA A
Benjamin Samelson-Jones¹, Peter Cygan², Stacy Croteau³, Huyen Tran⁴, Margaret Ragni⁵, Jerome Teitel⁶, John Rasko ⁷, Spencer Sullivan ⁸, Jill Moormeier⁹, Kristina Haley¹⁰, Kristen Jaworski¹¹, Amy MacDougall¹¹, Alexander Long ¹¹, Savina Jaeger ¹¹, Tiffany Chang¹¹, Gallia Levy¹¹. ¹Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Childrena, Philadelphia, PA, USA. ²Department of Medicine, Division of Blood and Vascular Disorders, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. ³Department of Pediatrics, Harvard Medical School, and the Division of Hematology and Oncology, Boston Childrena, Boston, MA, USA. ⁴Australian Centre for Blood Diseases, Monash University, Melbourne, Australia. ⁵Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. ⁶St Michael's Hospital Haemophilia Treatment Centre, University of Toronto, Toronto, ON, Canada. ⁷Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, and the Gene and Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia. ⁸Mississippi Center for Advanced Medicine, Madison, MS, USA. ⁹Department of Medicine, UMKC School of Medicine, Kansas City, MO, USA. ¹⁰Department of Pediatrics, Oregon Health a Science University, Portland, OR, USA. ¹¹Spark Therapeutics, Inc, Philadelphia, PA, USA

10:45

PROPHYLACTIC TREATMENT OF ACQUIRED VON WILLEBRAND DISEASE IN NON-HUMAN PRIMATES WITH VGA039, AN ANTI-PROTEIN S MONOCLONAL ANTIBODY
Benjamin Kim, Ian Huck, Lilley Leong, Tony Byun, Aline He, Abel Silva, Joanne Chan, Young Cho, Stephen J. Moore, Graham Parry, Sandip Panicker. Vega Therapeutics, Inc, South San Francisco, CA, USA

11:00

RECOMBINANT ADAMTS13 PROPHYLAXIS IN PATIENTS WITH CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA: INTERIM ANALYSIS FROM THE PHASE 3B CONTINUATION STUDY
Paul Coppo¹, Parth Patwari², BjAprn MellgAyrd², Hong Li², Marie Scully³, Masanori Matsumoto⁴, Jerzy Windyga⁵, Thomas L Ortel⁶, Spero Cataland⁷, Paul KnApbl⁸, Ziqiang Yu⁹, Ana Antun¹⁰, Sami Ibrahimi¹¹, Doug Criger², Linda T Wang². ¹APHP. 6a, Paris, France. ²Takeda Development Center Americas, Inc, Cambridge, MA, USA. ³University College London Hospitals NHS Foundation Trust, London, United Kingdom. ⁴Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara, Japan. ⁵Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland. ⁶Duke University, Durham, NC, USA. ⁷Department of Internal Medicine, Ohio State University, Columbus, OH, USA. ⁸Department of Medicine 1, Division of Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria. ⁹National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. ¹⁰Department of Hematology and Medical Oncology, School of Medicine, Emory University, Atlanta, GA, USA. ¹¹Department of Internal Medicine, Section of Hematology and Oncology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA

11:15

INITIAL REPORT OF PART B PHASE 1/2 EFFICACY AND SAFETY RESULTS FOR BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH RELAPSED IMMUNE THROMBOCYTOPENIA
Nichola Cooper¹, A. J. Gerard Jansen², Jiri Mayer³, Michael D Tarantino⁴, Remco Diab⁵, Brad Ward⁶, Ahmed Daak⁶, David J Kuter⁷. ¹Hammersmith Hospital, London, United Kingdom. ²Erasmus MC, University Medical Center, Rotterdam, Netherlands. ³Masaryk University Hospital, Brno, Czech Republic. ⁴The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, IL, USA. ⁵Sanofi, Rotkreuz, LU, Switzerland. ⁶Sanofi, Cambridge, MA, USA. ⁷Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

SHORT TALKS - THROMBOSIS - INNOVATIONS IN AC
Chair/Organizer: Vinai Bhagirath, Sean Quinn
Sheraton Ballroom IV-V

10:45

APIXABAN AND RIVAROXABAN VERSUS WARFARIN AS ATRIAL FIBRILLATION OR VENOUS THROMBOEMBOLISM TREATMENT IN SEVERELY OBESE PATIENTS: A MULTICENTER RETROSPECTIVE ANALYSIS
Paul Dobry^{1, 2}, Stephanie Edwin¹, Susan Szpunar³, Christopher Giuliano^{1, 2}. ¹Department of Pharmacy, Ascension St. John Hospital, Detroit, MI, USA. ²Department of Pharmacy Practice, Wayne State University, Detroit, MI, USA. ³Department of Medical Education, Ascension St. John Hospital, Detroit, MI, USA

11:00

UNRAVELING THE ANTICOAGULANT FUNCTIONS OF FV USING MONOCLONAL ANTIBODIES
Sean Quinn¹, Francis Ayombil¹, Matthew Bunce¹, Rodney M. Camire^{1, 2}. ¹Department of Pediatrics, The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. ²The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

11:15

THE ANTICOAGULATED TRAUMA PATIENT IN THE WILDERNESS
Emma DeLoughery, Thomas DeLoughery. Oregon Health a Science University, Portland, OR, USA

11:45 - 12:45 PM

SATELLITE SYMPOSIUM

MORE THAN CARRIERS: RECOGNIZING AND MANAGING WOMEN AND GIRLS WITH HEMOPHILIA (SPONSORED BY NOVO NORDISK)
Chicago Ballroom IX-X

To highlight Novo Nordisks long-standing commitment to women and girls with rare bleeding disorders, this interactive program will discuss the unique challenges women and girls with hemophilia experience and will highlight the serious consequences that may arise in those who are not diagnosed and treated appropriately. Many women and girls are more than carriers, and they may experience added complications during menstruation, pregnancy, labor, and delivery. Practical guidance for managing hemophilia in women and girls will be presented, including available resources for providers and patients

REAL-WORLD EXPERIENCES WITH ALTUVIIIO [ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC- VON WILLEBRAND FACTOR XTEN FUSION PROTEIN]: A FIRST-IN-CLASS TREATMENT OPTION (SPONSORED BY SANOFI)
Chicago Ballroom VI

Join us for a conversation about the mechanism of extension, pharmacokinetics, efficacy, dosing and safety information from the XTEND-1 clinical trial, as well as real-world clinical cases with ALTUVIIIO. This presentation will feature a live patient perspective.

12:45 - 1:30 PM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Riverwalk AB

A1. ANTICOAGULATION CLINICS

201

LONGITUDINAL CHANGES IN HEALTH-RELATED QUALITY OF LIFE (HRQL) DURING ANTICOAGULATION THERAPY IN CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM TREATMENT
Taylor A Hopper¹, Eva Ordonez Mazariegos², Andrea Jimena Morales Arteaga³, Cristhiam M Rojas Hernandez². ¹The University of Texas Health Science Center at Houston, Houston, TX, USA. ²The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ³Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, Mexico

A2. PLATELET ACTIVATION AND BIOCHEMISTRY

202

PLATELET INDICES IN HEALTHY PREGNANCIES
Laura M. Dionisio, Giovani M. Favero. State University of Ponta Grossa, Ponta Grossa, Brazil

A4. DISORDERS OF PLATELET NUMBER OR FUNCTION

203

PREVALENCE AND OUTCOMES OF HEPARIN-INDUCED THROMBOCYTOPENIA IN INFLAMMATORY BOWEL DISEASE: A DECADE STUDY
Ayobami Olafimihan¹, Ekrem Turk¹, Praise fawehinmi², Gbolahan Olatunji³, Emmanuel Kokori³, Aderinto Nicholas ⁴, Alejandro Vallejo¹, Nkechi Akata⁵, Shaka Hafeez¹. ¹John H. Stroger Jr Hospital, Chicago, IL, USA. ²Southern Illinois University Edwardsville, Edwardsville, IL, USA. ³University of Ilorin, Ilorin, Nigeria. ⁴Ladoke Akintola University of Technology, Ogbomosho, Nigeria. ⁵Meharry Medical College, Nashville, TN, USA

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

204

FIXED-DOSING OF 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE FOR REVERSAL OF ANTICOAGULATION: EVALUATING THE EFFECTIVENESS, SAFETY, AND COST SAVINGS
Amer Al Homssi¹, Ryan Lokkesmoe¹, Ryan Powers¹, Benjamin Jung², Lisa Baumann Kreuziger³. ¹Medical College of Wisconsin, Milwaukee, WI, USA. ²Froedtert Health, Milwaukee, WI, USA. ³Versiti Blood Research Institute, Milwaukee, WI, USA

205

STRUCTURED EDUCATION FOR NEWLY DIAGNOSED PERSONS WITH VON WILLEBRAND DISEASE: A HEMOPHILIA TREATMENT CENTER QUALITY IMPROVEMENT PROJECT ABSTRACT
Dominique N. Barclay, Sarah E. Gonzales, Marsha Hurn, Amanda Kilgore, Jesla Ryan, Jonathan C. Roberts, Michael D. Tarantino. Bleeding and Clotting Disorders Institute, Peoria, IL, USA

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

206

SAFETY AND EFFICACY OF THE ANTI-TISSUE FACTOR PATHWAY INHIBITOR MARSTACIMAB IN PARTICIPANTS WITH SEVERE HEMOPHILIA WITHOUT INHIBITORS: RESULTS FROM THE PHASE 3 BASIS TRIAL AND ONGOING LONG-TERM EXTENSION STUDY
Suchitra S. Acharya¹, Davide Matino², Andrew Palladino³, Eunhee Hwang³, Regina McDonald⁴, Carrie Turich Taylor⁵, John Teeter⁵. ¹Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, Northwell Health, New Hyde Park, NY, USA. ²McMaster University, 237 Barton St. East, Hamilton, ON, Canada. ³Pfizer Inc, Collegeville, PA, USA. ⁴Pfizer Inc, New York, NY, USA. ⁵Pfizer Inc, Groton, CT, USA

207

EFFICACY AND SAFETY OF EPTACOG BETA FOR BLEED TREATMENT IN ADULTS AND ADOLESCENTS WITH HEMOPHILIA B AND INHIBITORS DURING PERSEPT 1
Meera Chitlur¹, Yasmina Abajas², Suchitra Acharya³, Sanjay Ahuja⁴, Jonathan Bernstein⁵, Elizabeth Bowhay-Carnes⁶, Brandon Hardesty⁷, Jonathan C. Roberts^{8, 9}, Vanessa Salinas¹⁰, Craig Seaman¹¹, Robert Sidonio Jr. ¹², Daniel Bonzo¹³, Jim Phipps¹⁴, Thomas Wilkinson¹⁵, Guy Young¹⁶. ¹Central Michigan University College of Medicine/Childrena, Detroit, NY, USA. ²Hemophilia and Thrombosis Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ³Cohen Childrena, New Hyde Park, NY, USA. ⁴Rainbow Babies a Childrena, Cleveland, OH, USA. ⁵Hemophilia Center of Central Pennsylvania, Hershey Medical Center, Hershey, PA, USA. ⁶UT Health San Antonio, San Antonio, TX, USA. ⁷Indiana Hemophilia a Thrombosis Center, Indianapolis, IN, USA. ⁸Bleeding a Clotting Disorders Institute, Peoria, IL, USA. ⁹Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA. ¹⁰Center for Inherited Blood Disorders, Orange, CA, USA. ¹¹Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA. ¹²Aflac Cancer and Blood Disorders Center and Emory University, Atlanta, GA, USA. ¹³LFB-USA, Inc, Framingham, MA, USA. ¹⁴HEMA Biologics, LLC, Louisville, KY, USA. ¹⁵GLOVAL LLC, Broomfield, CO, USA. ¹⁶Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

208

ACCESS TO FACTOR VIII AND FACTOR IX TO PERSONS WITH HEMOPHILIA IN ARKANSAS: A QUALITY IMPROVEMENT STUDY
Divyaswathi Citla-Sridhar^{1, 2}, Kara Burge², Jean Aroom³, Justine Kaplan³, Shelley Crary^{1, 2}. ¹University of Arkansas for Medical Sciences, Little Rock, AR, USA. ²Arkansas Childrena, Little Rock, AR, USA. ³American Thrombosis and Hemostasis Network, Rochester, NY, USA

209

DISEASE BURDEN, QUALITY OF LIFE, AND TREATMENT PATTERNS IN PATIENTS WITH HEREDITARY FACTOR X DEFICIENCY: ANALYSIS OF DATA FROM THE HEREDITARY FACTOR X DEFICIENCY IN AMERICA SURVEY
Kim Clark¹, Denise A. Garner², Amy Wu², Lorie Mody², Jaymin Patel², Brian Branchford³. ¹Kedrion Biopharma, INC, Fort Lee, NJ, USA. ²AESARA, INC, Chapel Hill, NC, USA. ³Versiti Blood Research Institute, Medical College of Wisconsin, and Children's Wisconsin, Milwaukee, WI, USA

210

ELEVATED PROTEIN C IS PROTECTIVE AGAINST POST THROMBOTIC SYNDROME
Zijun He¹, Vivian Thompson¹, Dianne Thornhill¹, Rick Shearer¹, Christine Baird², Marilyn Manco-Johnson¹. ¹University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ²University of Colorado Anschutz Medical Campus Research Laboratory, Aurora, CO, USA

211

PROPHYLACTIC OR POST-TRAUMATIC TREATMENT OF HYPOFIBRINOGENEMIA AND DYSFIBRINOGENEMIA WITH FIBRGYA IN EIGHT CLINICAL CASES
Jessica N. Mistretta, Kristin T. Ansteatt, Michael D. Tarantino. Bleeding and Clotting Disorder Institute, Peoria, IL, USA

212

REAL-WORLD USE OF RECOMBINANT FACTOR IX FUSION PROTEIN IN PREVIOUSLY UNTREATED PATIENTS WITH CONGENITAL HEMOPHILIA B FROM THE ATHN 8 STUDY
Courtney D. Thornburg¹, Martin Chandler², Lynn Malec³, Matthew Manuel², Carrie O'Neill², Michael Recht^{4, 5}, Elizabeth Taggart², Hongseok Kim⁶, Vidhi Desai⁶, Hiren Shah⁶, Shannon L. Carpenter⁷. ¹Rady Childrena, San Diego, CA, USA. ²American Thrombosis and Hemostasis Network, Rochester, NY, USA. ³Versiti Blood Research Institute, Waukesha, WI, USA. ⁴Yale University School of Medicine, New Haven, CT, USA. ⁵National Bleeding Disorders Foundation, New York, NY, USA. ⁶CSL Behring, King of Prussia, PA, USA. ⁷Childrena, Kansas City, MO, USA

213

THE EFFECT OF BUDD-CHIARI SYNDROME (BCS) IN HOSPITALIZED HEPATOCELLULAR CARCINOMA PATIENTS (HCC): A NATIONWIDE ANALYSIS.
Ekrem G Turk, Ayobami Olafimihan, Khaldun Obeidat, Youjin Oh, Lina James, Angelo Caputi Zuniga, Alejandro Vallejo. John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA

A8. ANTITHROMBOTIC THERAPY

215

ANTI-FACTOR XI ANTIBODIES TARGETING THE APPLE 2 DOMAIN AND THE CATALYTIC DOMAIN EXERT DISTINCT IN VITRO INHIBITORY PROFILES ON COAGULATION FUNCTION
Dan Chalothorn, KehDih Lai, Weizhen Wu, Holly Sorenson, George Ehrlich, Ashique Rafique, Ishita Chatterjee, Kei Saotome, Matthew Franklin, Lori Morton. Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA

216

ANTITHROMBOSIS STEWARDSHIP AS A KEY DRIVER WITHIN A VTE CENTER OF EXCELLENCE - AMBITION INVESTIGATORS
Angela M. Martoccia Grabazs, Preeyaporn Sarangarm, Sundeep S. Guliani, Jonathan L. Marinaro, Allison E. Burnett. University of New Mexico Hospital, Albuquerque, NM, USA

217

ANTICOAGULATION STEWARDSHIP: APPROPRIATE USE OF APIXABAN AND RIVAROXABAN FACTOR XA LEVELS IN THE EMERGENCY DEPARTMENT
Firas Quran, Sara Zochert, Michael Gulseth, Alicia Martin. Sanford USD Medical Center and Hospital, Sioux Falls, SD, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

218

CELLULAR INDICES OF DVT
Priyanka Kavdikar¹, Ragini Mohan¹, Neha Thomas^{1, 3}, Fakiha Siddiqui², Atul Laddu¹, Jawed Fareed², Nysha Reddy¹. ¹Global Thrombosis Forum, Suwanee, GA, USA. ²Loyola University, Chicago, IL, USA. ³University of Westminster, London, United Kingdom

219

ARE MEDICAL LEARNERS ADEPT AT RECOGNIZING HEAVY VAGINAL BLEEDING?
Fartoon M Siad¹, Andrea Lausman², Filomena Meffe², Carolyn Snider³, Martina Trinkaus^{1, 4}, Michelle Sholzberg^{1, 4}. ¹Department of Medicine, University of Toronto, Toronto, ON, Canada. ²Department of Obstetrics and Gynecology, Toronto, ON, Canada. ³Division of Emergency Medicine, Toronto, ON, Canada. ⁴Division of Hematology/Oncology, St. Michaela, Toronto, ON, Canada

1:30 - 3:00 PM

HEMOSTASIS

IDENTIFICATION AND MANAGEMENT OF ACQUIRED BLEEDING IN THE ACUTE CARE SETTING
Chair/Organizer: Bethany Samuelson Bannow, Roy Khalife
Sheraton Ballroom I-II

1:30

REVIEW OF AQUIRED FACTOR DEFICIENCIES
Davide Matino.

2:00

LABORATORY TOOLS TO IDENTIFY ACQUIRED COAGULATION FACTOR ABNORMALITIES
Kristi Smock.

2:30

MANAGEMENT CONSIDERATIONS IN THE SURGICAL SETTING OF SUSPECTED AQUIRED FACTOR DEFICIENCIES
Rebecca Kruse-Jarres.

1:30 - 3:00 PM

THROMBOSIS / LABORATORY

TAKING THE RESULT TO THE PATIENT - LABORATORY CONSIDERATIONS IN THROMBOSIS
Chair/Organizer: William Dager, Leo Brandao
Chicago Ballroom VII

1:30

LABORATORY CONSIDERATIONS ON DOAC LEVELS (INCLUDING PRECISION AND WHAT WE'VE LEARNED FROM EXTERNAL QA&SEMI; COMMENT ON ANDEXANET)
Jim Zehnder.

2:00

DOAC - WHEN TO MEASURE LEVELS AND HOW TO INTERPRET: ON-TREATMENT VS THERAPEUTIC RANGE
Deb Siegal.

2:30

ADVANCES IN TESTING FOR APS - BEYOND SAPPORO (TITRES, ISOTYPES, NON-CRITERIA ANTIBODIES)
Tom Ortel.

1:30 - 3:00 PM

BASIC SCIENCE

UNBIASED TECH APPROACHES FOR HEMATOLOGICAL DISCOVERIES
Chair/Organizer: Jordan Shavit, Laura Haynes
Sheraton Ballroom IV-V

1:30

DEEP MUTATIONAL SCANNING TO PROBE FUNCTION OF COAGULATION PROTEINS
Laura Haynes.

2:00

GENETIC ENGINEERING OF MEGAKARYOCYTES TO UNCOVER FUNCTIONS OF PLATELET PROTEINS
Jesse Rowley.

2:30

MASS SPECTROMETRY GLYCOMICS AND DETERMINATION OF GPIB GLYCOSITES
Marie Hollenhorst .

3:00 - 5:00 PM

POSTER SESSION

ONLINE POSTER SESSION
On-Demand/Online

THE ROLE OF FIBRINOGEN IN CHANGING THE HEMOSTASIS OF PATIENTS WITH NEOPLASIA AND THEIR INFLUENCE ON THE MICROCIRCULATORY BED OF THE LUNGS AND CONTROL BY ANTICOAGULANTS
Vira A. Barilka, Volodymyr L. Matlan, Sofia V. Prymak, Olha O. Shalay, Vasyl L. Novak. SI qInstitute of Blood Pathology and Transfusion Medicine of NAMS of Ukraineq Lviv Ukraine, Lviv, Ukrenia

ANTITHROMBOTIC STEWARDSHIP AND HEALTH EQUITY IN PERIPHERAL ARTERY DISEASE
Kelly M. Rudd^{1, 2}, Kristie K. Roberts¹, Cooper M. Hamilton². ¹Oklahoma State University Center for Health Sciences Center College of Osteopathic Medicine, Tulsa, OK, USA. ²Oklahoma State University Center for Health Sciences Center College of Osteopathic Medicine, Tahlequah, OK, USA

PLATELET IMMUNOPHENOTYPE INDUCED BY THE SPIKE (S) PROTEIN AND THE RBD DOMAIN OF SARS-COV-2 VIRUS.
Alan Cano-Mendez, Nallely Garcia-Larragoiti, Yesenia Ambriz-Murillo, Patricia Guzman-Cansino, Alejandra Ochoa-Zarzosa, Martha Eva Viveros-Sandoval. Universidad Michoacana de San NicolAis de Hidalgo, Morelia, Mexico

CORRELATION BETWEEN ABO BLOOD TYPES AND DISEASE SEVERITY IN SICKLE CELL ANEMIA: IMPLICATIONS FOR THROMBOSIS AND HEMOSTASIS.
George M Bassey¹, Titilope A Adeyemo^{1, 2}, Ann A Ogbenna^{1, 2}, Abiola B Bolarinwa¹, Ademola S Adewoyin², Emmanuel Iyere¹. ¹Lagos University Teaching Hospital, Lagos, Nigeria. ²College of Medicine University of Lagos, Lagos, Nigeria

THE PREVALENCE OF THROMBOTIC EVENTS REPORTED FOLLOWING SARS-COV2 VACCINE RECEIPT: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
Jennifer DiRaimo¹, Caroline Kruse¹, Kate Foster¹, Alexandra Kruse^{1, 2}, Howard Liebman³, Craig Kessler⁴. ¹Platelet Disorder Support Association, Cleveland, OH, USA. ²Tulane University School of Medicine, New Orleans, LA, USA. ³Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Norris Comprehensive Cancer Center, Los Angeles, CA, USA. ⁴Vincent Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA

INVESTIGATING INTER-ASSAY VARIABILITY BETWEEN DOAC CALIBRATED ANTI-FACTOR XA ASSAYS: A SUBSTUDY OF THE PAUSE TRIAL
Ryan Baker¹, Rita Selby^{2, 3}, Karen A. Moffat^{4, 5}, Melanie St John⁵, Alex C. Spyropoulos^{6, 7, 8}, Sam Schulman⁹, James Douketis⁹. ¹Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. ²Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. ³Department of Medicine, University of Toronto, Toronto, ON, Canada. ⁴Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada. ⁵Department of Medicine, McMaster University, Hamilton, ON, Canada. ⁶The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA. ⁷Institute of Health System Science - The Feinstein Institutes for Medical Research, Manhasset, NY, USA. ⁸Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, NY, USA. ⁹Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada

CHIEF: A RETROSPECTIVE SELF-CONTROL STUDY OF CHILDREN
Daniel Mashiach^{1, 2}, Patrice Mead¹, Kendall Carneiro¹, Jemily Malvar¹, Guy Young^{1, 3}. ¹Childrena, Los Angeles, CA, USA. ²WesternU College of Osteopathic Medicine of the Pacific, Pomona, CA, USA. ³Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

THE EVALUATION OF MRX PT DOAC ASSAY FOR DETECTION OF CLINICALLY RELEVANT FACTOR XA INHIBITOR DRUG LEVELS
Brittany MA Salter¹, Karen A Moffat^{1, 2, 3}, Stephen A Carlino³, Liselotte OnelApv⁴, Sarah Ge¹, Marina Atalla¹, Raymond Melika¹, Saumya Bansal¹, Siraj Mithoowani¹, Mark Crowther^{1, 2}. ¹Department of Medicine, McMaster University, Hamilton, ON, Canada. ²Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. ³Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada. ⁴Nordic Biomarker, UmeAy, Sweden

A RETROSPECTIVE STUDY OF ACQUIRED VON WILLEBRAND SYNDROME IN MYELOPROLIFERATIVE NEOPLASMS
Mohammed Al Sharif ^{1, 2}, Brian Harnett ³, Subia Tasneem ¹, Brian Leber ^{4, 5}, Christopher Hillis ⁵, Catherine P. M. Hayward ^{1, 3, 4}. ¹Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. ² Department of Pathology and Laboratory Medicine, King Abdullah Bin Abdulaziz University Hospital, Princess Nourah University, Riyadh, Saudi Arabia. ³ Department of Medicine, McMaster University, Hamilton, ON, Canada. ⁴ Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada. ⁵ Hematology/Oncology, Juravinski Cancer Center, Hamilton, ON, Canada

DEVELOPMENT OF A PATIENT REPORTED OUTCOME MEASURE TO STUDY QUALITY OF LIFE IN BLEEDING DISORDER OF UNKNOWN CAUSE
Callie Berkowitz¹, Supreet Goraya², Alice Ma¹, Nigel Key¹, Angela Stover³. ¹Division of Hematology and Blood Research Center, University of North Carolina, Chapel Hill, NC, USA. ²Department of Maternal, Child, and Family Health, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA. ³Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA

USING A THROMBODYNAMICS TEST FOR DIAGNOSTICS OF HYPERCOAGULATION IN CANCER PATIENTS AND PREDICTION OF THROMBOEMBOLIC COMPLICATIONS: PRELIMINARY RESEARCH RESULTS.
Irina Dudina¹, Ekaterina Koltsova^{2, 3}, Irina Nigmatullina¹, Yana Akhmadiyarova¹, Olga Kostash¹, Anna Chankina¹, Daniil Stroyakovskiy¹. ¹State Budgetary Healthcare Institution Moscow City Oncology Hospital No. 62 of the Moscow City Health Department, Russian Federation, Moscow, 143515, Moskovskaya area, Krasnogorsk urban district, Istra village, building 27, Moscow, Russia. ²Federal State Budgetary Institution Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation, Russian Federation, Moscow, 117198, Samory Machel street, building 1, Moscow, Russia. ³Federal State Budgetary Institution of Science Center for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, Russian Federation, Moscow, 109029, Srednyaya Kalitnikovskaya street, building 30, Moscow, Russia

COMPARATIVE ANALYSIS OF BLEEDING AND THROMBOTIC RISKS AMONG IMMUNE CHECKPOINT INHIBITORS: INSIGHTS FROM THE FDA ADVERSE EVENT REPORTING SYSTEM
Emily L Paton¹, Emma P Deloughery^{1, 2}. ¹Oregon Health a Science University, Department of Medicine, Portland, OR, USA. ²Oregon Health a Science University, Department of Medicine, Division of Hematology a Medical Oncology, Portland, OR, USA

ACQUIRED HEMOPHILIA SECONDARY TO THE TRANSPLANTATION OF HEMATOPOIETIC PROGENITORS. A SYSTEMATIC REVIEW
Rafael Pichardo-Rodriguez¹, Cristhian Gonzales- Rospigliosi¹, Dalia Pimentel-Ramirez¹, Aracely Carrasco-Espinoza¹, Lara Vela-Rojas¹, Diana-Cristina RamAsrez-Meyhuay¹, Jhony A. De La Cruz-Vargas¹, Alfredo Wong Chang², Cristobal Frutos³. ¹Instituto de Investigaciones en Ciencias BiomAcdicas (INICIB). Universidad Ricardo Palma, Lima, Peru. ²Unidad de Trasplante de MAcdula A, Lima, Peru. ³Instituto de PrevisiA³n Social, Asuncion, Paraguay

EFFECT OF ACUTE DEEP VEIN THROMBOSIS IN PATIENTS WITH LUNG CANCER IN ACUTE DEEP VEIN THROMBOSIS (DVT): A STUDY OF THE NATION INPATIENT SAMPLE
Maria Cristina Cuartas- Mesa, Nana Yaa Ampaw, Edwin Gwira- Tamattey, Enrique Martinez- Trevino, Alejandro Nieto- Dominguez , Ekrem Turk . John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA

GATHERING AND DISSEMINATING STANDARDIZED GENE THERAPY DATA - THE WORLD FEDERATION OF HEMOPHILIA GENE THERAPY REGISTRY
Barbara A. Konkle¹, Flora Peyvandi², Mayss Naccache³, Wolfgang Miesbach⁴, Brian O'Mahony⁵, Steven W. Pipe⁶, Mark W. Skinner⁷, Donna Coffin³, Glenn F. Pierce³. ¹University of Washington, Seattle, WA, USA. ²Department of Pathophysiology and Transplantation, UniversitAn degli Studi di Milano, Milan, Italy. ³World Federation of Hemophilia, Montreal, QC, Canada. ⁴University Hospital Frankfurt, Frankfurt, Germany. ⁵Irish Haemophilia Society, Dublin, Ireland. ⁶University of Michigan, Ann Arbor, MI, USA. ⁷Institute for Policy Advancement Ltd, Washington, DC, USA

PREDICTING PULMONARY EMBOLISM IN PATIENTS WITH DEEP VENOUS THROMBOSIS IN THE EMERGENCY DEPARTMENT: A QUANTITATIVE D-DIMER DIAGNOSTIC APPROACH FROM A HOSPITAL IN MEXICO CITY
Oscar A Lopez Ramos¹, David G Gonzalez Sanchez ², Oliver A Gomez-Gutierrex², Hector Segura Marin², Andrea Rojas Guevara ¹, Arely Gayosso Godinez ¹. ¹Hospital EspaApol, Mexico City, Mexico. ²Tecnologico de Monterrey, Monterrey, Mexico

3:00 - 3:45 PM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Riverwalk AB

A1. ANTICOAGULATION CLINICS

301

NOVEL POINT-OF-CARE (POC) PLATFORM FOR DIRECT ORAL ANTICOAGULANTS (DOAC) AND VITAMIN K ANTAGONISTS (AVK) TESTING: MICRODOAC AND MICROINR ASSAYS
Tamara Montes, Mikel Santiago, Irene Mijangos. RaD Department, iLine Microsystems S. L, San SebastiAin/Donostia, Spain

A2. PLATELET ACTIVATION AND BIOCHEMISTRY

302

RED BLOOD CELL HAEMOLYSIS AND PLATELET ACTIVATION : THE FORGOTTEN PLAYERS OF HYPERCOAGULABILITY
Neha Thomas, Stipo Jurcevic. University of Westminster, London, United Kingdom

A4. DISORDERS OF PLATELET NUMBER OR FUNCTION

303

HMB-001 FOR PROPHYLACTIC TREATMENT OF GLANZMANN THROMBASTHENIA: PHASE 1/2 TRIAL INSIGHTS
Suthesh Sivapalaratnam^{1, 2}, Gillian Lowe³, Ashley Gosnell⁴, Ulrike Lorch⁵, Jigar Amin⁴, Catherine Rea⁴. ¹Queen Mary University of London, London, United Kingdom. ²Barts Health NHS Trust, London, United Kingdom. ³Comprehensive Care Haemophilia Centre, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom. ⁴Hemab Therapeutics, Cambridge, MA, USA. ⁵Richmond Pharmacology, London, United Kingdom

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

304

INVESTIGATING THE RELATIONSHIP BETWEEN D DIMER LEVELS AND VISCOELASTIC CHARACTERISTICS OF BLOOD CLOTS
Eli J Foster, Nathaniel Hai, Seemantini K Nadkarni. Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

305

TRANSFUSION TRENDS IN THE OBSTETRIC POPULATION WITH ANALYSIS OF A SOFT STOP TRANSFUSION EMR ALERT
Maren Plant¹, Sophia Cordes¹, Caroline Bereuter¹, Jaclyn Phillips¹, Xiomara Fernandez², Homa Ahmadzia¹. ¹Department of Obstetrics and Gynecology, George Washington University, Washington, DC, USA. ²Department of Pathology, George Washington University, Washington, DC, USA

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

306

THE BURDEN OF HEMOPHILIA IN THE US: METHODS AND RESULTS FROM THE COST OF HEMOPHILIA: A SOCIOECONOMIC SURVEY (CHESS) US (2022)
Randall Curtis¹, Maria Elisa Mancuso^{2, 3}, Enrico Ferri Grazzi⁴, Donna Coffin⁵, Brian O'Mahony^{6, 7}, Clive Smith⁸, DaniAcl Anibal GarcAsa Diego⁹, Matteo Arzenton¹⁰, Thomas SanniAc¹¹, Fiona Brennan¹², Tom Burke^{4, 13}, Sarah Brighton⁴. ¹Hematology Utilization Group Study (HUGS), Walnut Creek, CA, USA. ²Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Italy. ³Humanitas University, Pieve Emanuele, Milan, Italy. ⁴HCD Economics, Knutsford, United Kingdom. ⁵World Federation of Hemophilia, Montreal, QC, Canada. ⁶Irish Haemophilia Society Ltd, Dublin, Ireland. ⁷Trinity College, Dublin, Ireland. ⁸The Haemophilia Society, London, United Kingdom. ⁹FederaciA³n EspaApola de Hemofilia (FedHemo), Madrid, Spain. ¹⁰Italian Federation of Haemophilia Associations (FedEmo), Rome, Italy. ¹¹Association FranAsaise des HAcmophiles (AFH), Paris, France. ¹²Faculty of Health and Social Care, University of Chester, Chester, United Kingdom

307

HEMOSTATIC OUTCOME OF SURGICAL PROCEDURES IN PATIENTS WITH HEMOPHILIA RECEIVING CONCIZUMAB PROPHYLAXIS: DATA FROM THE PHASE 3 EXPLORER7 AND EXPLORER8 TRIALS
Matthew Evans¹, Anthony K. C. Chan², Chris Barnes³, Mary Mathias⁴, Silvia Linari⁵, Francisco-JosAc LA³pez-Jaime⁶, Lone Hvitfeldt Poulsen⁷, Julien Bovet⁸, Jan Odgaard-Jensen⁸, Tadashi Matsushita⁹, Emily K. Waters¹⁰. ¹Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. ²McMaster Childrena, Hamilton, ON, Canada. ³Royal Childrena, Victoria, Australia. ⁴Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. ⁵Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy. ⁶Hospital Regional Universitario de MAilaga, MAilaga, Spain. ⁷The Haemophilia Centre, Department of Haematology, Aarhus University Hospital, Aarhus, Denmark. ⁸Novo Nordisk A/S, SAcborg, Denmark. ⁹Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan. ¹⁰Novo Nordisk Inc, Plainsboro, NJ, USA

308

ATHN TRANSCENDS - HEMOPHILIA GENE THERAPY OUTCOMES ARM: A LONG-TERM FOLLOW-UP STUDY ON SAFETY AND EFFECTIVENESS OF GENE THERAPY IN PEOPLE WITH HEMOPHILIA
Staber Janice¹, Blanca Salazar², Roberto Guillen-Gonzalez², Michael Recht^{3, 4}, Tammuella Chrisentery-Singleton⁵, Ulrike Reiss⁶. ¹Iowa Hemophilia and Thrombosis Center University of Iowa Stead Family Childrena, Iowa City, IA, USA. ²CSL Behring, King of Prussia, PA, USA. ³National Bleeding Disorders Foundation, New York, NY, USA. ⁴Yale University School of Medicine, New Haven, CT, USA. ⁵American Thrombosis and Hemostasis Network, Rochester, NY, USA. ⁶Hemophilia Treatment Center St. Judea, Memphis, TN, USA

309

A PHASE 3, RANDOMIZED, ACTIVE-CONTROL STUDY OF FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE VERSUS FROZEN PLASMA IN BLEEDING ADULT CARDIAC SURGERY PATIENTS
Keyvan Karkouti^{1, 2}, Jeannie Callum^{3, 4}, Kenichi Tanaka⁵, Deep Grewal², Cristina Solomon⁶, Sigurd Knaub⁶, Sylvia Werner⁷, Gita Pezeshki⁷, Jerrold H. Levy⁸. ¹University of Toronto, Toronto, ON, Canada. ²University Health Network, Toronto, ON, Canada. ³Queena, Kingston, ON, Canada. ⁴Kingston Health Sciences Centre, Kingston, ON, Canada. ⁵University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. ⁶Octapharma AG, Lachen, Switzerland. ⁷Octapharma USA, Paramus, NJ, USA. ⁸Duke University School of Medicine, Durham, NC, USA

310

VITAMIN D DEFICIENCY IN PERSONS WITH BLEEDING DISORDERS - A SINGLE CENTER EXPERIENCE
Dan Leary, Mindy Simpson, Lisa Boggio. Rush Hemophilia and Thrombophilia Center, Chicago, IL, USA

311

GENOMIC VARIATIONS IN FACTOR VII DEFICIENCY PREDISPOSING TO THROMBOPHILIA: A CASE OF SINUS VENOUS THROMBOSIS IN A PATIENT WITH FACTOR VII DEFICIENCY
Aaron C. Lobo ¹, Paridhi Ghai¹, Fabricio M Webber¹, David H. Witt². ¹Bridgeport Hospital/Yale New Haven Health, Bridgeport, CT, USA. ²Yale Smilow Cancer Center/Yale school of Medicine, Trumbull, CT, USA

312

EMICIZUMAB PROPHYLAXIS FOR THE TREATMENT OF INFANTS WITH SEVERE HAEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: PRIMARY ANALYSIS OF THE HAVEN 7 STUDY
Steven W. Pipe¹, Peter Collins², Christophe Dhalluin³, Gili Kenet^{4, 5}, Christophe Schmitt³, Muriel Buri³, VAsctor JimAcnez-Yuste⁶, Flora Peyvandi^{7, 8}, Guy Young⁹, Johannes Oldenburg¹⁰, Maria Elisa Mancuso^{11, 12}, Kaan Kavakli¹³, Anna Kiialainen³, Markus Niggli³, Tiffany Chang¹⁴, Michaela Lehle 3, Karin Fijnvandraat¹⁵. ¹University of Michigan, Ann Arbor, MI, USA. ²School of Medicine, Cardiff University, Cardiff, United Kingdom. ³F. Hoffmann-La Roche Ltd, Basel, Switzerland. ⁴Sheba Medical Center, Ramat Gan, Israel. ⁵Tel Aviv University, Tel Aviv, Israel. ⁶Hospital Universitario La Paz-IdiPaz, Universidad AutA³noma, Madrid, Spain. ⁷Fondazione IRCCS Caa, Milan, Italy. ⁸UniversitAn degli Studi di Milano, Milan, Italy. ⁹Childrena, Los Angeles, CA, USA. ¹⁰Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany. ¹¹IRCCS Humanitas Research Hospital, Rozzano, Italy. ¹²Humanitas University, Pieve Emanuele, Milan, Italy. ¹³Ege University Faculty of Medicine Children's Hospital, Izmir, Turkey. ¹⁴Spark Therapeutics, Inc, San Francisco, CA, USA. ¹⁵University of Amsterdam, Amsterdam, Netherlands

313

A MULTI-YEAR FOLLOW-UP STUDY OF FIDANACOGENE ELAPARVOVEC GENE THERAPY FOR HEMOPHILIA B
Benjamin J. Samelson-Jones^{1, 2}, Lindsey A. George^{1, 2}, John E. J. Rasko^{3, 4}, Adam Giermasz⁵, Jerome M. Teitel⁶, Catherine E. McGuinn⁷, Jonathan M. Ducore⁵, Sharon Pennington⁸, Katherine A. High², Jeremy Rupon⁹, Francesca Biondo¹⁰, Annie Fang¹¹, Lynne M. Smith⁹, Matko Kalac¹¹, Amit Chhabra¹¹, Frank Plonski⁹. ¹Childrena, Philadelphia, PA, USA. ²Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. ³Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney, Australia. ⁴Gene and Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. ⁵Hemophilia Treatment Center, University of California Davis, Sacramento, CA, USA. ⁶St. Michaela, Toronto, ON, Canada. ⁷Weill Cornell Medicine, New York, NY, USA. ⁸Mississippi Center for Advanced Medicine, Madison, MS, USA. ⁹Pfizer Inc, Collegeville, PA, USA. ¹⁰Pfizer Srl, Rome, Italy. ¹¹Pfizer Inc, New York, NY, USA

314

EMERGENCY DEPARTMENT UTILIZATION IN A PATIENT COHORT WITH HEMOPHILIA: A SINGLE CENTRE EXPERIENCE
Kelsey Uminski^{1, 2}, Natalia Rydz^{1, 2}, Dawn Goodyear^{1, 2}. ¹Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Calgary, AB, Canada. ²Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Calgary, AB, Canada

A8. ANTITHROMBOTIC THERAPY

315

DUAL DIRECT ORAL ANTICOAGULANT THERAPY IN CHALLENGING THROMBOSIS: A CASE SERIES
Heather McPhaden¹, Chornenki Nicholas¹, Peterson Erica¹, Lai Chieh Min Benjamin^{1, 2}, Lee Agnes¹. ¹The University of British Columbia, Department of Medicine, Division of Hematology, Vancouver, BC, Canada. ²The University of British Columbia Centre for Blood Research, Vancouver, BC, Canada

316

RECURRENT VENOUS THROMBOEMBOLISM IN A SYMPTOMATIC HEMOPHILIA A CARRIER
Natalie/A Montanez^{1, 3}, Joanna/M Larson^{1, 3}, Miguel/A Escobar^{1, 2, 3}. ¹University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Houston, TX, USA. ²University of Texas Health Science Center of Houston, McGovern Medical School, Department of Internal Medicine, Houston, TX, USA. ³Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA

317

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF HUMAN PLASMA DERIVED ANTITHROMBIN (ATENATIV) IN HEPARIN-RESISTANT CARDIAC SURGERY PATIENTS
Cristina Solomon¹, Catrin Argyle¹, Jerrold H. Levy², Sylvia Werner¹. ¹Octapharma AG, Lachen, Switzerland. ²Duke University School of Medicine, Durham, NC, USA

318

AN IMPLEMENTATION DILEMMA: REJECTION OF THROMBOPROPHYLAXIS RECOMMENDATIONS IN THE CHILDREN'S LIKELIHOOD OF THROMBOSIS (CLOT) TRIAL
Shannon C. Walker, Benjamin French, Ryan P. Moore, Henry J. Domenico, C. Buddy Creech, Amanda S. Mixon, Daniel W. Byrne, Allison P. Wheeler. Vanderbilt University Medical Center, Nashville, TN, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

319

OVERCOMING DISTANCE AND TRAVEL BARRIERS FOR VIRGINIA BLEEDING DISORDERS TREATMENT CENTERS: A COMPREHENSIVE NEEDS ASSESSMENT
Erika J Martin, Lauren C Dunn, Katherine L Bains, Janice G Kuhn. Virginia Commonwealth University, Richmond, VA, USA

320

DOAC'S IN THE ELDERLY
Abhinav Paknikar¹, Keerti Chakravarthy¹, Fakiha Siddiqui², Atul Laddu¹, Jawed Fareed², Aarushi Dua¹, Anish Joshi¹. ¹Global Thrombosis Forum, Suwanee, GA, USA. ²Loyola University, Chicago, IL, USA

3:45 - 5:15 PM

THROMBOSIS

HEALTH CARE INEQUITITY IN THE TREATMENT OF VTE
Chair/Organizer: Anne Rose, Vinai Bhagirath
Sheraton Ballroom I-II

3:45

DISPARITIES IN ANTICOAGULATION CARE ACROSS THE SPECTRUM
Sara Vasquez.

4:15

TREATMENT OF VTE IN RURAL AMERICA
Jennifer Young.

4:45

MATERNAL MORTALITY AND PULMONARY EMBOLISM IN MINORITY POPULATIONS
Leslie Lake.

3:45 - 5:15 PM

HEMOSTASIS / LABORATORY

LAB SUPPORT OF CLINICAL DECISION-MAKING IN THE CRITICALLY ILL BLEEDING PATIENT
Chair/Organizer: Marian Rollins-Raval, Allison Wheeler
Chicago Ballroom VII

3:45

HOW THE LAB CAN SUPPORT CLINICAL DECISION-MAKING IN ACUTE CRITICAL BLEEDING
Nathan Nielsen.

4:15

REVIEW OF THE USE OF CONCENTRATED CLOTTING FACTORS VERSUS BLOOD PRODUCTS
Laura Downey.

4:45

COAGULATION BIOMARKERS AND LABORATORY SUPPORT OF CRITICALLY ILL PATIENTS
Sabrina Racine-Brzostek.

3:45 - 5:15 PM

BASIC SCIENCE

TAKE A HIKE MICKEY- NOVEL T&H INSIGHTS FROM NON-MURINE ANIMALS
Chair/Organizer: Bobby Lee, Anna Dahlgren
Sheraton Ballroom IV-V

3:45

MULTISPECIES ANALYSIS OF THE ERAD PATHWAY IN PLATELET FUNCTION
Anna Dahlgren.

4:15

DECIPHERING PLATELET COLD STORAGE LESION IN HIBERNATING RODENTS
Scott Cooper.

4:45

DISCOVERING NOVEL PRO-COAGULANT AGENTS FROM SNAKE VENOM
Raymond Adili.

5:30 - 6:30 PM

SATELLITE SYMPOSIUM

CLINICAL & PATIENT PERSPECTIVE: A TREATMENT FOR ADULTS WITH ACUTE HEPATIC PORPHYRIA, INCLUDING ACUTE INTERMITTENT PORPHYRIA (SPONSORED BY: ALNYLAM PHARMACEUTICALS)
Chicago Ballroom VI

Acute hepatic porphyria (AHP) is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain. Led by Dr. Angelika Erwin, a consultant of Alnylam Pharmaceuticals, this presentation will provide a disease overview and review the clinical profile of a treatment for adults with AHP, featuring Phase 3 Study results and open-label extension data. Attendees will also hear from an AHP patient who will share their experience with the disease and treatment. Please join Alnylam Pharmaceuticals and Dr. Erwin to learn more about this treatment for adults with AHP. Dinner will be provided for attendees.

GENE THERAPY FOR HEMOPHILIA B: SHARING EXPERIENCES IN REAL-WORLD SETTINGS (SPONSORED BY: CSL BEHRING)
Chicago Ballroom IX-X

Despite meaningful improvements in treatment for hemophilia B, there remains a need for new therapeutic options that will reduce bleeds, reduce or eliminate the need for routine factor IX prophylaxis, and provide long-term benefits of sustained factor IX activity levels. The first ever FDA-approved gene therapy for hemophilia B is designed to reduce the burden of disease on patients lives by addressing these unmet needs. Join our educational product theater session as a team of hemophilia B experts discuss the clinical data and the patient and HCP journey towards treatment as well as share their clinical experiences with gene therapy for hemophilia B. Continuing education credits will not be offered for this program.

7:00 - 8:00 PM

SATELLITE SYMPOSIUM

UNLOCKING THE NEXT STEP IN GENE THERAPY FOR HEMOPHILIA: THE END OF THE BEGINNING? (SPONSORED BY CSL BEHRING)
On-Demand/Online